FI3634975T3 - 15-beeta-[3-propanamido]substituoitujen estra-1,3,5(10)-trien-17-onien 17-oksiimeja käytettäväksi 17-beeta-hydroksisteroididehydrogenaasien inhiboimisessa - Google Patents
15-beeta-[3-propanamido]substituoitujen estra-1,3,5(10)-trien-17-onien 17-oksiimeja käytettäväksi 17-beeta-hydroksisteroididehydrogenaasien inhiboimisessa Download PDFInfo
- Publication number
- FI3634975T3 FI3634975T3 FIEP18733926.2T FI18733926T FI3634975T3 FI 3634975 T3 FI3634975 T3 FI 3634975T3 FI 18733926 T FI18733926 T FI 18733926T FI 3634975 T3 FI3634975 T3 FI 3634975T3
- Authority
- FI
- Finland
- Prior art keywords
- methyl
- decahydro
- cyclopenta
- propanamide
- hydroxyimino
- Prior art date
Links
- LGHBWDKMGOIZKH-CBZIJGRNSA-N 3-Deoxyestrone Chemical class C1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 LGHBWDKMGOIZKH-CBZIJGRNSA-N 0.000 title 1
- 108020005199 Dehydrogenases Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 51
- 150000001875 compounds Chemical class 0.000 claims 28
- -1 fluoropyridinyl Chemical group 0.000 claims 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- 125000005842 heteroatom Chemical group 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 229920006395 saturated elastomer Polymers 0.000 claims 8
- 229910052717 sulfur Inorganic materials 0.000 claims 8
- 239000011593 sulfur Substances 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000005641 Adenomyosis Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 206010071289 Lower urinary tract symptoms Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000037093 Menstruation Disturbances Diseases 0.000 claims 2
- 206010027339 Menstruation irregular Diseases 0.000 claims 2
- FHJXHRLIYOMRPX-UHFFFAOYSA-N O1CCN(CC1)C=1C=CC(=NC=1)C(C(=O)N)C Chemical compound O1CCN(CC1)C=1C=CC(=NC=1)C(C(=O)N)C FHJXHRLIYOMRPX-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 208000013507 chronic prostatitis Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 239000013256 coordination polymer Substances 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 201000006828 endometrial hyperplasia Diseases 0.000 claims 2
- 201000009274 endometriosis of uterus Diseases 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000007106 menorrhagia Diseases 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000006405 methylpyridazinyl group Chemical group 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000003903 pelvic floor Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 201000001514 prostate carcinoma Diseases 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000001635 urinary tract Anatomy 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 claims 2
- BGBLBEYVGBEGFU-UHFFFAOYSA-N 2-(4-fluoropyridin-2-yl)propanamide Chemical compound FC1=CC(=NC=C1)C(C(=O)N)C BGBLBEYVGBEGFU-UHFFFAOYSA-N 0.000 claims 1
- KCMDPJQUHYXHFV-UHFFFAOYSA-N 2-(4-methoxypyridin-2-yl)propanamide Chemical compound COC1=CC(=NC=C1)C(C(=O)N)C KCMDPJQUHYXHFV-UHFFFAOYSA-N 0.000 claims 1
- CJIILXBBYWTAGI-UHFFFAOYSA-N 2-(5-propan-2-ylpyridin-2-yl)propanamide Chemical compound C(C)(C)C=1C=CC(=NC=1)C(C(=O)N)C CJIILXBBYWTAGI-UHFFFAOYSA-N 0.000 claims 1
- NVOBPQRSCXAUGH-UHFFFAOYSA-N 2-(6-methoxypyridazin-3-yl)propanamide Chemical compound COC1=CC=C(N=N1)C(C(=O)N)C NVOBPQRSCXAUGH-UHFFFAOYSA-N 0.000 claims 1
- GSJNWDDYAYSNEV-UHFFFAOYSA-N 2-(6-methylpyridazin-3-yl)propanamide Chemical compound CC1=CC=C(N=N1)C(C(=O)N)C GSJNWDDYAYSNEV-UHFFFAOYSA-N 0.000 claims 1
- FZRAUIYUWVOLOL-UHFFFAOYSA-N 2-pyridazin-3-ylpropanamide Chemical compound NC(=O)C(C)C1=CC=CN=N1 FZRAUIYUWVOLOL-UHFFFAOYSA-N 0.000 claims 1
- ZCMILLAOXOEWPJ-UHFFFAOYSA-N 2-pyridin-2-ylpropanamide Chemical compound NC(=O)C(C)C1=CC=CC=N1 ZCMILLAOXOEWPJ-UHFFFAOYSA-N 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 101000870345 Vasconcellea cundinamarcensis Cysteine proteinase 1 Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012433 hydrogen halide Substances 0.000 claims 1
- 229910000039 hydrogen halide Inorganic materials 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
- C07J41/0016—Oximes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0044—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an estrane or gonane skeleton, including 18-substituted derivatives and derivatives where position 17-beta is substituted by a carbon atom not directly bonded to another carbon atom and not being part of an amide group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20175530 | 2017-06-08 | ||
| PCT/FI2018/050427 WO2018224736A2 (en) | 2017-06-08 | 2018-06-07 | Therapeutically active steroidal derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3634975T3 true FI3634975T3 (fi) | 2024-05-03 |
Family
ID=62716091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18733926.2T FI3634975T3 (fi) | 2017-06-08 | 2018-06-07 | 15-beeta-[3-propanamido]substituoitujen estra-1,3,5(10)-trien-17-onien 17-oksiimeja käytettäväksi 17-beeta-hydroksisteroididehydrogenaasien inhiboimisessa |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10717761B2 (es) |
| EP (1) | EP3634975B1 (es) |
| JP (3) | JP7064515B2 (es) |
| KR (1) | KR102420512B1 (es) |
| CN (2) | CN115716860A (es) |
| AU (1) | AU2018279205B2 (es) |
| CA (1) | CA3066196C (es) |
| CL (1) | CL2019003562A1 (es) |
| DK (1) | DK3634975T3 (es) |
| EA (1) | EA201992826A1 (es) |
| FI (1) | FI3634975T3 (es) |
| HR (1) | HRP20240679T1 (es) |
| HU (1) | HUE066375T2 (es) |
| IL (2) | IL294140B2 (es) |
| LT (1) | LT3634975T (es) |
| MX (2) | MX2019014677A (es) |
| NZ (1) | NZ760155A (es) |
| PL (1) | PL3634975T3 (es) |
| PT (1) | PT3634975T (es) |
| RS (1) | RS65529B1 (es) |
| SG (1) | SG11201911776PA (es) |
| SI (1) | SI3634975T1 (es) |
| UA (1) | UA126342C2 (es) |
| WO (1) | WO2018224736A2 (es) |
| ZA (1) | ZA201908404B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7417608B2 (ja) * | 2018-12-05 | 2024-01-18 | フォレンド ファーマ リミテッド | １７－ｈｓｄ１阻害剤としての１６（１７）位でピラゾール環と縮合しているエストラ－１，３，５（１０）－トリエン化合物 |
| CN114644673B (zh) * | 2020-12-19 | 2023-12-26 | 上海喀露蓝科技有限公司 | 一种雌二醇衍生物、其制备方法及其在医药上的用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1429104A (zh) | 1998-03-11 | 2003-07-09 | 内部研究股份有限公司 | 5型和3型17β－羟基类固醇脱氢酶的抑制剂及其用法 |
| GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
| JP4320252B2 (ja) | 2001-09-06 | 2009-08-26 | シェーリング コーポレイション | アンドロゲン依存性疾患の処置のための１β−ヒドロキシステロイドデヒドロゲナーゼ３型インヒビター |
| EP1436281B1 (en) | 2001-10-17 | 2010-06-16 | Schering Corporation | Piperidine- and piperazineacetamides as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| WO2004046111A1 (en) | 2002-11-18 | 2004-06-03 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| EP1572299B1 (en) | 2002-12-17 | 2008-09-24 | Schering Corporation | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| WO2004085345A2 (en) | 2003-03-21 | 2004-10-07 | Yale University | 15α-SUBSTITUTED ESTRADIOL CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS |
| GB0306718D0 (en) | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
| US20040224935A1 (en) | 2003-04-07 | 2004-11-11 | Endorecherche, Inc. | Topical antiandrogenic steroids |
| US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| TWI331154B (en) * | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
| US8088758B2 (en) * | 2003-11-12 | 2012-01-03 | Abbott Products Gmbh | 17β-hydroxysteroid dehydrogenase type I inhibitors |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| DE102004032673A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 |
| DE102004032674A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
| US7575828B2 (en) | 2004-07-23 | 2009-08-18 | Kim Manufacturing Co. | Modular rack assemblies for sealed lead acid batteries |
| UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
| EP1888615B1 (en) | 2005-05-26 | 2012-05-16 | Abbott Products GmbH | 17 -hsd1 and sts inhibitors |
| US8030298B2 (en) | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| EP2125859B1 (en) | 2006-09-19 | 2013-05-15 | Abbott Products GmbH | Estratriene derivatives and their uses as 17beta-hydroxysteroid dehydrogenase inhibitors |
| JP5264760B2 (ja) | 2006-11-30 | 2013-08-14 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | １７β−ＨＳＤインヒビターとしての置換エストラトリエン誘導体 |
| US9284345B2 (en) | 2007-04-12 | 2016-03-15 | Endorecherche, Inc. | 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators |
| WO2010059943A2 (en) | 2008-11-20 | 2010-05-27 | President And Fellows Of Harvard College | Fluorination of organic compounds |
| JP2014508784A (ja) * | 2011-03-25 | 2014-04-10 | ユニヴェルシテ ラヴァル | １７β−ＨＳＤ１、１７β−ＨＳＤ３、および１７β−ＨＳＤ１０の阻害剤 |
| TW201534612A (zh) * | 2013-06-25 | 2015-09-16 | Forendo Pharma Ltd | 治療用活性雌三烯噻唑衍生物 |
| AR096727A1 (es) | 2013-06-25 | 2016-01-27 | Forendo Pharma Ltd | Derivados terapéuticamente activos de estratrien-tiazol |
| AR096728A1 (es) * | 2013-06-25 | 2016-01-27 | Forendo Pharma Ltd | Derivados de estratrieno-tiazol terapéuticamente activos |
| US10413557B2 (en) * | 2014-12-23 | 2019-09-17 | Forendo Pharma Ltd. | Prodrugs of 17.BETA.-HSD1-inhibitors |
| WO2016102775A1 (en) * | 2014-12-23 | 2016-06-30 | Forendo Pharma Ltd | PRODRUGS OF 17β-HSD1 -INHIBITORS |
-
2018
- 2018-06-07 KR KR1020207000499A patent/KR102420512B1/ko active IP Right Grant
- 2018-06-07 NZ NZ760155A patent/NZ760155A/en unknown
- 2018-06-07 PL PL18733926.2T patent/PL3634975T3/pl unknown
- 2018-06-07 CA CA3066196A patent/CA3066196C/en active Active
- 2018-06-07 EA EA201992826A patent/EA201992826A1/ru unknown
- 2018-06-07 MX MX2019014677A patent/MX2019014677A/es unknown
- 2018-06-07 HU HUE18733926A patent/HUE066375T2/hu unknown
- 2018-06-07 MX MX2022000747A patent/MX2022000747A/es unknown
- 2018-06-07 JP JP2019567580A patent/JP7064515B2/ja active Active
- 2018-06-07 WO PCT/FI2018/050427 patent/WO2018224736A2/en active Application Filing
- 2018-06-07 HR HRP20240679TT patent/HRP20240679T1/hr unknown
- 2018-06-07 US US16/002,227 patent/US10717761B2/en active Active
- 2018-06-07 RS RS20240572A patent/RS65529B1/sr unknown
- 2018-06-07 AU AU2018279205A patent/AU2018279205B2/en active Active
- 2018-06-07 LT LTEPPCT/FI2018/050427T patent/LT3634975T/lt unknown
- 2018-06-07 CN CN202211366607.2A patent/CN115716860A/zh active Pending
- 2018-06-07 IL IL294140A patent/IL294140B2/en unknown
- 2018-06-07 EP EP18733926.2A patent/EP3634975B1/en active Active
- 2018-06-07 CN CN201880048486.2A patent/CN110945007B/zh active Active
- 2018-06-07 PT PT187339262T patent/PT3634975T/pt unknown
- 2018-06-07 SG SG11201911776PA patent/SG11201911776PA/en unknown
- 2018-06-07 UA UAA201912052A patent/UA126342C2/uk unknown
- 2018-06-07 DK DK18733926.2T patent/DK3634975T3/da active
- 2018-06-07 FI FIEP18733926.2T patent/FI3634975T3/fi active
- 2018-06-07 SI SI201831096T patent/SI3634975T1/sl unknown
-
2019
- 2019-12-05 CL CL2019003562A patent/CL2019003562A1/es unknown
- 2019-12-05 IL IL271218A patent/IL271218A/en unknown
- 2019-12-17 ZA ZA2019/08404A patent/ZA201908404B/en unknown
-
2020
- 2020-06-05 US US16/893,494 patent/US11254703B2/en active Active
-
2022
- 2022-01-11 US US17/573,081 patent/US20220127303A1/en not_active Abandoned
- 2022-02-07 JP JP2022017522A patent/JP7401576B2/ja active Active
-
2023
- 2023-12-07 JP JP2023207267A patent/JP2024028916A/ja active Pending
-
2024
- 2024-04-19 US US18/640,607 patent/US20240309043A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021200639B2 (en) | PD-1/PD-L1 inhibitors | |
| JP6666263B2 (ja) | グルタミナーゼの新規阻害剤 | |
| JP7128816B2 (ja) | 疾患の治療のための二重ロイシンジッパー（ｄｌｋ）キナーゼのビシクロ［１．１．１］ペンタン阻害剤 | |
| JP5930278B2 (ja) | Ｍｌｋ阻害剤および使用方法 | |
| JP2019527202A5 (es) | ||
| US10023576B2 (en) | Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors | |
| CA2565852C (en) | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | |
| JP2017533925A5 (es) | ||
| CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| EP3558979A1 (en) | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors | |
| JP2020512343A5 (es) | ||
| JP7125952B2 (ja) | 腫瘍を治療するための薬剤の製造におけるｂｔｋ阻害剤との組み合わせでのｅｚｈ２阻害剤の使用 | |
| RU2009125578A (ru) | Новые замещенные диазаспиропиридиноновые производные для применения в лечении мсн-1-опосредованных заболеваний | |
| CN107207531B (zh) | 作为TGF-β抑制剂的稠合的咪唑衍生物 | |
| FI3634975T3 (fi) | 15-beeta-[3-propanamido]substituoitujen estra-1,3,5(10)-trien-17-onien 17-oksiimeja käytettäväksi 17-beeta-hydroksisteroididehydrogenaasien inhiboimisessa | |
| JP2016523911A (ja) | Ｂｔｋ阻害薬としての一級カルボキサミド類 | |
| EA019506B1 (ru) | Конденсированные гетероциклические производные и их применение | |
| WO2009104019A1 (en) | Combination therapy 238 | |
| JP2020506951A5 (es) | ||
| MXPA06002880A (es) | Derivados 1,1,1-trifluoro-4-fenil-4-metil-2-(1h-pirrolo `2,3-cipiridin-2-ilmetil) pentan-2-ol y compuestos relacionados como ligandos glucorticoides para el tratamiento de enfermedades inflamatorias y diabetes. | |
| CN109562190A (zh) | 抗egfr抗体药物偶联物 | |
| CA2509406A1 (en) | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
| CA2559128A1 (en) | Kinase inhibitors | |
| JP2022531088A (ja) | Ｊａｋ阻害剤としての置換ピロロピリジン | |
| CA2499903A1 (en) | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists |